keyboard_arrow_up

Psoriasis – Identifying and Commercializing First-in-Class Innovation Market

RnRMarketResearch.com adds report “Frontier Pharma: Psoriasis – Identifying and Commercializing First-in-Class Innovation” to its store.

Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly impairs the patient’s physical and mental wellbeing. The primary cause of psoriasis is unknown, as are the mechanisms that lead to immune cells directing inflammatory responses towards the skin. Within the lucrative autoimmune market, the psoriasis market has grown considerably due to the repositioning of all three marketed Tumor Necrosis Factor (TNF) inhibitors: Humira (adalimumab) and Enbrel (etanercept) which were originally approved for rheumatoid arthritis, and also Remicade (infliximab), the first biologic to be approved for Crohn’s disease, an autoimmune disease which largely affects the gastrointestinal system.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 The Case for Innovation
2.1 Growing Opportunities for Biologic Products
2.2 Diversification of Molecular Targets
2.3 Innovative First-in-Class Product Developments Remain Attractive
2.4 Changes in the Clinical and Commercial Environment Will be More Favorable to Products That Target Niche Indications and Patient Populations
2.5 Innovation in Psoriasis

Request a sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=181818 .

3 Clinical and Commercial Landscape
3.1 Disease Introduction
3.2 Epidemiology
3.3 Etiology
3.3.1 Genetic Predisposition
3.3.2 Environmental Factors
3.4 Pathophysiology
3.4.1 Keratinocytes
3.4.2 Dendritic Cells
3.4.3 T-Cells
3.4.4 Angiogenesis
3.4.5 Growth Factors
3.5 Symptoms and Co-morbidities
3.5.1 Skin Manifestations
3.5.2 Psoriatic Arthritis
3.5.3 Uveitis

Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=181818 .

3.5.4 Cardiovascular Disease
3.5.5 Psychological Impact
3.6 Diagnosis of Psoriasis
3.6.1 Diagnosis of Psoriatic Arthritis
3.7 Treatment
3.7.1 Pharmacological Therapies
3.7.2 Topical Medications
3.7.3 Systemic Medications
3.7.4 Non-Pharmacological Therapies
3.7.5 Combination and Rotational Therapies
3.8 Overview of Marketed Products for Psoriasis
3.8.1 Oral Non-Biologic DMARDs
3.8.2 Off-Label Non-Biologic DMARDs
3.8.3 Biologics
3.8.4 Comparative Efficacy and Safety of Marketed Products
3.8.5 Unmet Need

4 Assessment of Psoriasis Pipeline and Innovation
4.1 Overview
4.2 Comparative Efficacy and Safety of Pipeline Programs
4.3 Comparative Distribution of Programs in the Psoriasis Market and Pipeline by Therapeutic Target Family
4.4 Comparative Distribution of Programs with First-in-Class and Established Molecular Targets
4.5 Pipeline Programs Targeting Established Molecular Targets
4.6 First-in-Class Pipeline Programs with Novel Molecular Targets

Complete report available @ http://www.rnrmarketresearch.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-market-report.html .

5 First-in-Class Target and Pipeline Program Evaluation
5.1 Cytokines and Receptors
5.1.1 Pipeline Programs Targeting Tumor Necrosis Factor Receptors
5.1.2 Pipeline Programs Targeting Interleukin-6
5.1.3 Pipeline Programs Targeting Interleukin-8
5.1.4 Pipeline Programs Targeting Interleukin-17
5.1.5 Pipeline Programs Targeting Interferon-?
5.2 B and T Cell Antigens
5.2.1 Pipeline Programs Targeting Cluster of Differentiation 4
5.2.2 Pipeline Programs Targeting Cluster of Differentiation 28
5.3 Intracellular Kinases
5.3.1 Pipeline Programs Targeting Interleukin-1 Receptor-Associated Kinase-4
5.4 Nuclear Receptors
5.4.1 Pipeline Programs Targeting Retinoic Acid Receptor-Related Orphan Receptor
5.5 Growth Factors
5.5.1 Pipeline Programs Targeting Transforming Growth Factor-ß Receptor
5.5.2 Pipeline Programs Targeting Insulin Receptor Substrate
5.6 Ion Channels
5.6.1 Pipeline Programs Targeting Calcium Release-Activated Calcium Channel
5.7 Integrins
5.7.1 Pipeline Programs Targeting Vascular Adhesion Protein-1
5.8 Other

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=181818 .

Browse Dermatology Therapeutics Industry Reports @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics .

About Us:

RnRMarketResearch.com is an online databas e of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple indus tries. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more.

Follow Us On

Twitter : https://twitter.com/#!/RnRMR

Facebook : http://www.facebook.com/pages/RnR-Market-Research/413488545356345

Google Plus : https://plus.google.com/u/0/104156468549256253075/